Model reduction in mathematical pharmacology
Abstract
In this paper we present a framework for the reduction and linking of physiologically based pharmacokinetic (PBPK) models with models of systems biology to describe the effects of drug administration across multiple scales. To address the issue of model complexity, we propose the reduction of each type of model separately prior to being linked. We highlight the use of balanced truncation in reducing the linear components of PBPK models, whilst proper lumping is shown to be efficient in reducing typically nonlinear systems biology type models. The overall methodology is demonstrated via two example systems; a model of bacterial chemotactic signalling in Escherichia coli and a model of extracellular regulatory kinase activation mediated via the extracellular growth factor and nerve growth factor receptor pathways. Each system is tested under the simulated administration of three hypothetical compounds; a strong base, a weak base, and an acid, mirroring the parameterisation of pindolol, midazolam, and thiopental, respectively. Our method can produce up to an 80% decrease in simulation time, allowing substantial speed-up for computationally intensive applications including parameter fitting or agent based modelling. The approach provides a straightforward means to construct simplified Quantitative Systems Pharmacology models that still provide significant insight into the mechanisms of drug action. Such a framework can potentially bridge pre-clinical and clinical modelling - providing an intermediate level of model granularity between classical, empirical approaches and mechanistic systems describing the molecular scale.
Keywords
Mathematical pharmacology Model reduction Systems pharmacology PBPKIntroduction
Within the past decade quantitative systems pharmacology (QSP) has emerged as a novel discipline proposing the use of integrated, multidisciplinary models that bridge the gap between the biological insight of modelling target scale effects of drug action systemically with pharmacokinetic/pharmacodynamic (PKPD) modelling approaches traditionally found in the field of clinical pharmacology [49, 59, 61, 65]. The aim of such an approach is to obtain mechanistic models of drug action that enable the prediction of drug dose-exposure, efficacy and potential side effects for a given subject and dose a priori. Some researchers [60] see the approach as providing a partial remedy to the current issues of candidate attrition troubling the pharmaceutical industry and a stepping stone towards an ultimate goal of personalised medicine.
The core principle of QSP is the bringing together of data and knowledge from basic biological research and the multiple stages of drug development into a single multiscale quantitative modelling framework describing drug action. At its simplest this means the integration of cell level signalling detail (e.g. protein-protein interaction networks) with multiscale models that span the effect of drug binding at the molecular level up to the whole-body effects of drug administration, absorption and clearance. The approach has a number of potential benefits compared with empirical compartmental modelling approaches commonly used to describe population PKPD. Firstly, it offers an integrated modelling approach to drug development bringing together experimental results from preclinical, animal and clinical studies into a unified quantitative model of drug action, enabling a more mechanistic approach to the study of translation. Secondly, it can provide greater insight into the mechanisms of action underlying drug efficacy and toxicity, with mathematical analysis of molecular scale signalling models potentially enabling the study and prediction of emergent cell scale network phenomena that may not have been predictable via traditional PKPD approaches. Thirdly, it can yield better mechanistic understanding of the possible causes of between-patient variability. Finally, it enables the integration of data from previous drug candidates of similar classes (failures and successes) that act on the same or related pathways. In doing so, it can provide a more nuanced framework for studying the causes of drug candidate failure and how they can be avoided in future.
Whilst QSP offers an approach for integrating knowledge across multiple scales in the prediction of drug efficacy, it raises a number of mathematical challenges [61]. These include developing the tools to create and validate multiscale models potentially ranging from the genetic to population level, surmounting the issues of practicability associated with highly complex, nonlinear models of biochemical reaction cascades, and addressing the general difficulties associated with meaningfully combining interdisciplinary data. In this paper we outline a framework for the creation of QSP models through the reduction and linkage of physiologically based pharmacokinetic (PBPK) models with reduced systems biology type models describing the biochemical activity of a drug at the cellular and intracellular scales.
Pharmacological modelling of drug disposition now commonly employs PBPK at multiple stages of research and development [17, 18, 32]. Such systems describe the movement of a drug throughout compartments corresponding to realistic tissues that span the entire body. PBPK models differ from the classical compartmental approaches to pharmacokinetic modelling in that they incorporate parameters informed via physiological and biological knowledge of the body in order to more mechanistically, as opposed to empirically, describe pharmacokinetic activity. Due to the higher dimensionality of these models, and associated issues of parameterisation to which such a modelling approach can lead, PBPK remains most commonly applied within the context of drug discovery and for the scaling of in vitro or animal studies of drug disposition. At clinical stages of drug development, PBPK can still find use in drug-drug interaction or pediatric studies, but where clinical trials are performed in order to initially fit models to in vivo experimental data, simpler and more empirical approaches to PK modelling still tend to be preferred. In part, this is due to the fact that PBPK models are often found to be structurally unidentifiable [64], greatly hindering their practical use in the context of clinical trial data. Partly in order to improve such properties of identifiability and to enable parameter fitting, publications concerning the reduction of PBPK models, have begun to emerge [57].
As an approach to mathematically modelling biological systems, systems biology differs philosophically from preceding approaches in that it attempts to describe cells and their signalling systems holistically [19, 20]. This enables the creation of models that incorporate explanatory power of underlying biological mechanisms at the cost of significant model complexity. This is typically achieved by describing systems at a molecular level of detail and showing how their interaction can produce larger scale phenomena of interest. Such approaches have gained some traction within a pharmacological setting due to their capacity to describe a drug’s mechanism of action physiologically.
Despite their potential usefulness, however, models attempting to span the scales of both PBPK and systems biology will typically be significantly too complex to be of practical use in a clinical setting. This complexity can be seen to stem from a number of common mathematical properties. For instance, such models will often possess a very large number of modelled species, concentrations and reactions. Such systems are often modelled using the theory of deterministic ordinary differential equations (ODEs) and as such can comprise tens to hundreds of state-variables. Such models thus often come with associated issues of high simulation time and numerical error. Models also frequently describe a wide range of kinetic rates observed across the multiple scales of drug action and as a result, portions of the system are likely to evolve on greatly different time-scales resulting in model stiffness. Such models are also usually nonlinear, which can prohibit a number of analytical approaches. Finally, due to the scope of these systems, it can simply prove too difficult to readily intuit or understand their biological implications. Often the parameter space is simply too large to convincingly explore or understand what variation in the parameterisation may mean.
One methodology for tackling a number of these issues, in an effort to bring understanding of the role of processes within and across scales, is model reduction. Model reduction here refers to any method designed to construct a simplified formulation of a model with which some set of the original dynamical behaviour can be satisfactorily approximated and within which some degree of predictive power is retained. A wide variety of such methods exist in the literature [2, 34, 47] and they have commonly been employed for alleviating issues of complexity in other fields of modelling (for example chemical engineering [34], control theory [44], and weather prediction [26]). Within the context of integrative QSP, model reduction can potentially be applied at multiple levels. In this paper we evaluate two particular uses in this context; firstly, model reduction can be used to yield a simplified description of the pharmacokinetic disposition of a drug that retains a physiological basis. Secondly, it be can be used to produce a reduced description of the biochemical activity of the drug at the target scale through the simplification of systems biology type models.
The simplification of PBPK models has been relatively well explored in the literature through the use of linear, proper lumping [4, 10, 12, 33, 37]. The aim is typically to reduce the more complex models of PBPK to the point where they can be fit against clinical trial data as in the case of traditional compartmental PK models [57]. Proper lumping has also seen application in the broader contexts of Systems Biology [7, 9, 21, 50, 51] and Systems Pharmacology [14] type models. Other model reduction approaches including time-scale exploitation [6, 13, 22, 23, 36, 39, 43, 52, 53, 54], sensitivity analysis [3, 8, 28, 29, 45], optimisation based approaches [1, 30, 38, 55] and balanced truncation [15, 27, 48] have also seen published application within a systems biology setting. Here, we focus specifically on two of these methods - proper lumping and balanced truncation. Proper lumping seeks to reduce a system by modelling the dynamical behaviour of subsets of the original state-variables en masse as opposed to individually. Meanwhile balanced truncation transforms the model’s state-variables into a form where those portions of the network least responsible for some input–output type relationship of interest can be easily removed.
The ideal scope and complexity of model depends necessarily on the specific questions that we are seeking to address, the level of approximation we are willing to accommodate, the prior knowledge we have at hand, and the actual data available. In practice, modelling often boils down to a balance between these factors. When constructing models from the ground up, these considerations often have to be repeatedly assessed—and discussions around how to achieve this do exist in the literature [63]. One of the key advantages of model reduction, however, is that we can instead start by constructing a complex model based upon the full extent of the literature available, and then use automated methods to reduce it down to a scale appropriate to its intended application. It is this approach that we seek to leverage throughout this paper—by first assembling a holistic, physiological description of a drug’s mechanism of action alongside its pharmacokinetic disposition, we then aim to apply model reduction to the individual components of this model in order to automatically extract a practical and usable system that retains an explicit link back to this physiological scale.
The literature concerning the other step of linking of PK modelling efforts with those of systems biology is less developed than that of model reduction. Krippendorff et al. [24] have demonstrated a simple linking procedure whereby a mass-action model is built integrating the whole-body and cellular scales. Both normal and diseased cells exist in a well-stirred compartment of the PK model each with receptors able to bind to the drug. They demonstrate that this approach can potentially be used to study how such differences in receptor affinity affects the clinical response of drugs with the same proposed mechanism of action. It is this approach to model linkage that we employ throughout our work.
Given the context outlined above, our paper demonstrates how methods of model reduction and model linkage can be brought together under a single framework in order to yield simplified Systems Pharmacology or enhanced pharmacodynamics models [16]. The developed methodology is applicable to models formulated using deterministic nonlinear and linear ODEs. For a given drug, the framework presented here starts with a model of PBPK and a relevant systems biology model describing the drug’s hypothesised mechanism of action at the target scale. The approach applies differing methods of model reduction to individual components of the network based on their suitability, and then recombines the reduced components to finally obtain a simplified system. This work is related to our previous paper [46] which developed a combined model reduction algorithm that sequentially applied multiple methods of reduction in order to obtain highly accurate reduced systems.The overall method, however, does not sequentially apply reduction methods, but instead seeks to decompose the overall network into linear and nonlinear sub-modules and then reduce them independently using the most appropriate method for each. By focusing on the maintenance of input–output relations for each sub-module throughout its reduction, we allow the overall model to remain highly accurate when recombined. As is demonstrated, these models continue to provide an accurate description of drug action across multiple scales whilst also having been reduced to a significantly more tractable size. Additionally, our approach in the reduction of PBPK models is differentiated from those previously published in that we seek to apply balanced truncation, as opposed to proper lumping, as a means of simplification. The framework is demonstrated using a generalised PBPK model and systems biology models of differing complexity: an 11 dimensional model of bacterial chemotactic signalling in Escherichia coli [56] and a 99 dimensional model of extracellular signal-regulated kinase (ERK) phosphorylation mediated via the epidermal growth factor (EGF) and nerve growth factor (NGF) receptor pathways [42].
Methodology
There are several possible approaches for the creation of a reduced model spanning the multiple scales of drug activity. This paper assumes that one begins with, or is able to develop, models of the drug’s pharmacokinetic behaviour and the target scale activity describing its proposed mechanism of action. The aim is then to create a single system encapsulating the dynamics of both models whilst also being simple enough to be practically usable within a clinical setting.
- 1.
Linking the models together initially and reducing the entire linked system under a single approach to obtain the reduced linked system; or
- 2.
Initially seeking to separate or decompose the constituent models into sub-modules with related properties. Then, seek to reduce these modules in isolation, using the most appropriate method of reduction for each model component. Finally we can then link the reduced modules together, again yielding a reduced linked system.
Whilst the first approach may allow a simpler mathematical implementation by only requiring a single model reduction approach, this fact is also its main disadvantage in that the method employed must be valid for all aspects of the model and is unlikely to be optimal for any of them. Instead this paper outlines the use of the second approach, which allows us to tailor the methods of model reduction to specific model components and hence obtain better, more accurate overall reduced systems. The reasons for wanting to achieve this are twofold.
Secondly, the timescales of PBPK models are typically significantly slower than those of biochemical reaction network models. As a result, reduction of the pre-linked system will often remove much more of the detail from the systems biology model which may not be ideal in the case where mechanistic explanatory power at this scale is intended to be retained.
The overall approach for achieving a reduced linked system proposed here is depicted in Fig. 3b. The method begins with the unreduced PBPK and systems biology intracellular biochemical reaction network models. To reduce the PBPK model we then decompose it into its linear and nonlinear components as previously described. Inputs and outputs are then defined based upon this decomposition, the specific modelled phenomena of interest, and to represent how the PK drives the modelled systems biology processes. Next the linear components of the model are reduced via balanced truncation under the defined input–output terms. All nonlinear components, typically including the biochemical reaction network, are then reduced via proper lumping. Finally, the reduced model components are then linked.
Given this overall framework, the remainder of this methodology section provides more specific, mathematical detail on the overall problem and a basic account of the reduction methods – proper lumping and balanced truncation.
Model reduction and approximation error
Whilst model input and output can be fairly abstract concepts, within a pharmacological context they can be reasonably concretely understood. In the case of a PBPK type model the input could, for example, describe the dosing regimen administered, whilst the output might correspond to the concentration of the compound in some subset of the modelled compartments. In the case of a systems biology type model describing a receptor signalling pathway, the input might represent the time-varying, extracellular concentration of a specific ligand, whilst the output may represent the concentration of a specific intracellular protein associated with a cellular response of interest.
It is important to note that all model reduction will result in some degree of error \(\varepsilon\). As a result the specific choice of reduced model to use in a given situation essentially boils down to a compromise between simplicity and accuracy. Inevitably this choice will depend upon the specific aims and context associated with the modelling work being performed, and as such it is hard to give a catch-all rule for choosing the best level of reduction to employ. In this paper we have selected the target of 5% error for our reduced linked models, and aimed to construct the minimal dimensional model that remains within this degree of error.
Proper lumping
There is a range of literature describing different approaches for finding the optimal lumping matrix L to produce a reduced system of dimension \(\hat{n}\) for a given system. Here we employ the scheme described by Dokoumetzidis and Aarons [9]. This algorithm runs an exhaustive search of possible lumping matrices to determine which produces the lowest error between simulation of the original model and the reduced model. To speed up this process, it is assumed (from justifications given in the original paper) that the lowest error k dimensional reduction obtained via lumping of an n dimensional system can also be found as the optimal lumping of two states in the \(k+1\) dimensional reduction. This yields a ‘forward selection’ strategy, where 2 of the state-variables are lumped at each step, which greatly decreases the combinatorial burden of possible lumping matrices that must be evaluated.
Balanced truncation
Balanced truncation is a method of model reduction for the simplification of systems describing an input–output type process. It is most commonly employed in the field of control theory and was originally devised in the early 1980s [31]. The method was further refined by a number of authors (e.g. [35]) and has subsequently become a well-developed one [11, 44]. Typically, it is used in the simplification of time-invariant, linear systems and seeks to remove those portions of the dynamics that contribute least to the overall input–output relationship of the model. As such it begins with systems in the form of Eq. (2) and assumes that A is a stable or Hurwitz matrix, such that its eigenvalues all have negative real components. This implies that the system is asymptotically stable; a property that will typically hold true for all biochemical systems.
Central to the application of balanced truncation to such a system are the concepts of observability and controllability. Broadly speaking, controllability asks to what degree the state-variables \({\varvec{x}}(t)\) of the system can be ‘moved’ or affected by the input \({\varvec{u}}(t)\). Meanwhile observability asks to what degree the state-variables of the system can be inferred or ‘observed’ from the output \({\varvec{y}}(t)\). Both concepts go some way to addressing a crucial question; to what extent and by what means does the input into the system affect its output?
To quantify these concepts requires the calculation of two matrices known as the controllability and observability Gramians (\({\mathcal{P}}\) and \({\mathcal{Q}}\), respectively) for the system. Once obtained, the aim is to find a balancing transformation for the system. This is a transformation of the state-variables for which the Gramians are equalised and diagonalised and which can be achieved via use of the singular value decomposition. As a result, the state-variables produced by such a transformation are somewhat obfuscated in terms of their meaning with respect to the original model. Much like other singular value decomposition based methodologies, such as the statistical method of principle component analysis, they instead represent orthogonal directions in state-space that, when treated as the new variables of our system, describe the input–output behaviour in order of contribution. Thus the first transformed state-variable accounts for the largest contribution to the input–output relationship and each succeeding component in turn describes the most of the input–output behaviour possible under the constraint that it is orthogonal to the preceding state-variables. By omitting or ‘truncating’ the transformed state-variables that contribute least to the input–output relationship we can construct a reduced model whilst losing only relatively little accuracy.
Whilst the state-variables themselves are obscured, it is always possible to obtain an accurate description of any of the defined outputs and there is no limit on the outputs that can be defined. This is achieved via use of a generalised right inverse, that, when applied to the reduced state-variables can be used to recover approximations of the original outputs based upon the reduced system.
Such an approach has significant advantages over proper lumping; firstly, it is designed for an input–output formulation which fits well within a pharmacokinetic context. Secondly, as is shown in Dullerud and Paganini [11], an a priori error bound can be obtained for reduction under balanced truncation. A more detailed description of the mathematical steps needed to calculate and apply such a balanced truncation is given in Appendix 3.
Results and discussion
Reducing a PBPK model
Here we demonstrate the application of balanced truncation in reducing a PBPK model. This serves two purposes. Firstly, it allows us to reduce the model in preparation for linking with a Systems Biology type model. Secondly, it allows us to compare reduction via balanced truncation with the more commonly employed approach of proper lumping.
Here we consider this general model within a control theoretic framework as earlier described by Eq. (1). When trying to understand how the administration of a particular drug propagates throughout the body, such a formulation of the problem represents a logical framework for its description. Mathematically, this model can therefore be represented by a 16 dimensional system of non-conserved, linear ODEs, which can be expressed in the form described by Eq. (2). In this case \(A\in {\mathbb{R}}^{16\times 16}\) is a matrix representing the kinetic rates with which the concentration of drug moves between the compartments and \({\varvec{x}}\in {\mathbb{R}}^{16}\) represents the vector of instantaneous drug concentrations in each of the physiological compartments. Our inputs, \({\varvec{u}}(t)\), represent the times and magnitudes of the doses administered. These doses are then mapped to the compartments to which they contribute by the matrix B. For instance, an orally administered drug would be mapped directly to the oral dosing compartment. The outputs, \({\varvec{y}}(t)\), and their mapping C from the original compartment concentrations are those combinations of the compartments that the modeller seeks to predict with the system. It is possible to simply set C equal to the identity matrix such that all compartments are considered, however it is often the case that only some subset of the compartments (often the intravenous and effective compartments) are of clinical relevance.
- Set 1:
The physiological parameters, found in Table 1. These parameters represent the various physiological properties of the individual to which the drug is administered. The values presented here represent a 70 kg male human with average measures of liver and kidney function, fractional tissue volumes, and blood flow from Jones and Rowland-Yeo [17].
- Set 2:
The compound-specific parameters, found in Table 2. These parameters represent specific properties of the drug that has been administered. Parameterisations for three specific compounds across a reasonable pH range are given here: a strong base represented by the beta-blocker pindolol, a weak base represented by the benzodiazepine midazolam, and an acid represented by the barbiturate thiopental. Compound specific parameters were taken from Pilari and Huisinga [4]. Tissue to plasma partition coefficients were then estimated via the formulae outlined by Rodgers et al. [40, 41].
Physiological parameters for the PBPK model shown in Fig. 4, their meaning, and the values used
Parameter | Meaning | Value |
---|---|---|
BW | Body weight (kg) | 70 |
QC | Cardiac output (L/h) | \(3.90\times 10^{2}\) |
MPPGL | mg microsomal protein per g liver | 45 |
FVad | Fractional volume of adipose (L/kg) | \(2.13\times 10^{-1}\) |
FVbo | Fractional volume of bone (L/kg) | \(8.56\times 10^{-2}\) |
FVbr | Fractional volume of the brain (L/kg) | \(2\times 10^{-2}\) |
FVgu | Fractional volume of the gut (L/kg) | \(1.71\times 10^{-2}\) |
FVhe | Fractional volume of the heart (L/kg) | \(4.7\times 10^{-3}\) |
FVki | Fractional volume of the kidneys (L/kg) | \(4.4\times 10^{-3}\) |
FVli | Fractional volume of the liver (L/kg) | \(2.1\times 10^{-2}\) |
FVlu | Fractional volume of the lungs (L/kg) | \(7.6\times 10^{-3}\) |
FVmu | Fractional volume of muscle (L/kg) | \(4\times 10^{-1}\) |
FVsk | Fractional volume of skin (L/kg) | \(3.71\times 10^{-2}\) |
FVsp | Fractional volume of the spleen (L/kg) | \(2.6\times 10^{-3}\) |
FVte | Fractional volume of testes (L/kg) | \(1\times 10^{-2}\) |
FVve | Fractional venous volume (L/kg) | \(5.14\times 10^{-2}\) |
FVar | Fractional arterial volume (L/kg) | \(2.57\times 10^{-2}\) |
FVpl | Fractional volume of plasma (L/kg) | \(4.24\times 10^{-2}\) |
FVrb | Fractional volume of red blood cells (L/kg) | \(3.47\times 10^{-2}\) |
FVre | Fractional volume of rest of body (L/kg) | \(9.98\times 10^{-2}\) |
FQad | Fractional adipose blood flow | \(5\times 10^{-2}\) |
FQbo | Fractional bone blood flow | \(5\times 10^{-2}\) |
FQbr | Fractional brain blood flow | \(1.2\times 10^{-1}\) |
FQgu | Fractional gut blood flow | \(1.46\times 10^{-1}\) |
FQhe | Fractional heart blood flow | \(4\times 10^{-2}\) |
FQki | Fractional kidney blood flow | \(1.9\times 10^{-1}\) |
FQh | Fractional hepatic blood flow (venous) | \(2.15\times 10^{-1}\) |
FQlu | Fractional lung blood flow | 1 |
FQmu | Fractional muscle blood flow | \(1.7\times 10^{-1}\) |
FQsk | Fractional skin blood flow | \(5\times 10^{-2}\) |
FQsp | Fractional spleen blood flow | \(1.72\times 10^{-2}\) |
Compound specific parameters for the PBPK model shown in Fig. 4 and their meaning
Parameter | Meaning | Pindolol | Midazolam | Thiopental |
---|---|---|---|---|
BP | Blood to plasma ratio | 0.81 | 0.53 | 0.88 |
\({fu_{p}}\) | Fraction unbound in plasma | 0.41 | 0.05 | 0.18 |
Ka | Rate constant of absorption (\(\mathrm{{h}}^{-1}\)) | 2.08 | 1.13 | 5.64 |
\({CL_{bl}}\) | Hepatic blood clearance (mL kg/min) | 4.20 | 8.70 | 2.02 |
Kpad | Adipose partition coefficient | 1.52 | 2.41 | 12.17 |
Kpbo | Bone partition coefficient | 2.79 | 2.26 | 1.64 |
Kpbr | Brain partition coefficient | 2.26 | 5.12 | 1.09 |
Kpgu | Gut partition coefficient | 9.01 | 5.38 | 2.03 |
Kphe | Heart partition coefficient | 8.43 | 2.25 | 1.72 |
Kpki | Kidney partition coefficient | 17.94 | 2.51 | 4.85 |
Kpli | Liver partition coefficient | 16.40 | 2.77 | 3.60 |
Kplu | Lung partition coefficient | 14.11 | 3.33 | 1.72 |
Kpmu | Muscle partition coefficient | 6.08 | 1.61 | 0.78 |
Kpsk | Skin partition coefficient | 5.13 | 7.84 | 1.25 |
Kpsp | Spleen partition coefficient | 11.70 | 1.47 | 0.94 |
We now seek to apply balanced truncation for the reduction of this system as compared with the linear, proper lumping approach as described by Pilari and Huisinga [4] which employs the algorithm originally developed by Dokoumetzidis and Aarons [9]. To test the application of balanced truncation we sought to reduce the model described above by treating the concentration of the drug in the venous compartment as the only output of interest. The dose was modelled as being orally administered in each case, with the timing and magnitude of these doses representing the model input. Given this framework, calculating reduced versions of the model via both proper lumping and balanced truncation under the given compound specific parameters yields the results given in Table 3.
Percentage maximal relative error, \(\varepsilon\), associated with the reduction of the PBPK model via both lumping and balanced truncation
Dimensions | Pindolol | Midazolam | Thiopental | |||
---|---|---|---|---|---|---|
Lumping (%) | BT (%) | Lumping (%) | BT (%) | Lumping (%) | BT (%) | |
13 | 0.02 | 0 | 0.02 | 0 | 0.02 | 0 |
12 | 0.04 | 0 | 0.02 | 0 | 0.03 | 0 |
11 | 0.08 | 0 | 0.03 | 0 | 0.08 | 0 |
10 | 0.20 | \(\approx 0\) | 0.27 | \(\approx 0\) | 0.10 | \(\approx 0\) |
9 | 0.23 | \(\approx 0\) | 0.43 | \(\approx 0\) | 0.41 | \(\approx 0\) |
8 | 0.44 | \(\approx 0\) | 0.57 | \(\approx 0\) | 1.00 | \(\approx 0\) |
7 | 4.15 | \(\approx 0\) | 2.41 | \(\approx 0\) | 3.34 | 0.01 |
6 | 4.72 | \(\approx 0\) | 2.93 | 0.05 | 12.36 | 0.14 |
5 | 7.94 | 0.21 | 10.47 | 0.18 | 3.88 | 0.14 |
4 | 15.11 | 0.19 | 3.84 | 1.01 | 21.85 | 4.43 |
3 | 26.87 | 7.86 | 11.29 | 5.41 | 20.03 | 8.13 |
2 | 37.68 | 72.67 | 19.71 | 10.99 | 77.71 | 40.82 |
1 | 67.13 | 71.17 | 209.29 | 86.79 | 73.80 | 37.78 |
Systems biology model reduction and linking
We now seek to demonstrate the potential application of our model linkage and reduction methodology via application to two example models. In the first instance we consider an 11 dimensional model of bacterial chemotaxis in E. coli - the modest scope of this model allows the application of our methods to be more easily intuited. After this we address a significantly more complex, 99 dimensional model describing the mediation of ERK activation via both the EGF and NGF receptor pathways. In both cases we employ pindolol, midazolam and thiopental as example compound specific parameterisations to represent a hypothetical drug acting on the pathways described. To demonstrate our approach, we begin by first reducing each model via lumping before linking their reduced forms with the reduced PBPK model detailed in the preceding section.
Note that the examples discussed do not relate to specific clinical cases of experimentally tested drugs, but are representative of a general case. Both examples do, however, represent receptor targets; the general methodology presented in this paper will work for any target type, but receptor signalling pathways are the most common variety of model found in the systems biology literature.
A model of bacterial chemotaxis
The first example is a model of chemotactic signalling in E. coli outlined in a 2009 paper by Tindall et al. [56]. A large body of literature exists around E. coli due to its popularity within experimental settings for its ease of growth and manipulation. It is a common, rod shaped, gram-negative bacteria with a large number of strains present in nature. The model discussed here pertains specifically to those strains that exhibit a chemotactic response. Chemotaxis is the process by which a cell senses an environmental chemical gradient and biases its movement towards those regions most suitable for growth and reproduction. In the model presented here, this process involves the transmembrane receptors on the surface of the bacterium sensing the local concentrations of an attractant or repellent; a decrease in attractant or an increase in repellent will cause the receptors to activate a signalling pathway inside the cell resulting in an increase of the intracellular concentration of the phosphorylated chemotactic Y protein, referred to here as \(\text{CheY}_P\). This concentration, in turn, modulates the flagellum’s movement, resulting in a change of direction for the cell.
- 1.
The attractant-receptor binding mimics the typical drug-receptor binding seen in QSP modelling with the chemotactic cell response acting as the clinical endpoint;
- 2.
Such signalling networks are typically not overly complex, but are large enough for model reduction to be warranted; and
- 3.
Chemotaxis is well characterised in the literature, and as such models are typically fully parameterised.
Hence, it is possible to consider the external concentration of the chemotactic attractant as the input into the system and the total concentration of \(\text{CheY}_P\) as the model’s output, the latter being strongly correlated with cell movement. Here we aim to create a linked reduced system bringing together a reduced version of the E. coli model with a reduced version of the PBPK model previously described. When the model is linked with a PBPK system, the concentration of the metabolised drug in the effective compartment is then treated as the total extracellular chemotactic attractant concentration. The full form of the chemotaxis model is given in detail in Additional file 1 - Supplementary Information.
In this instance, it was chosen that the E. coli cells were limited to the liver and that this represented the effective compartment. In the case of the input, it was modelled that a 150 mg dose of a chemotactic attractant was administered orally at \(t=0\) with the model parameterised using those values detailed in [56]. Additionally, the PBPK model again employed the parameterisations defined by Tables 1 and 2, using pindolol, midazolam and thiopental as example compound specific parameterisations.
Error results for the application of proper lumping to the E. coli chemotaxis model
Model dimensions | Lumping error (%) |
---|---|
6 | 0.15 |
5 | 0.51 |
4 | 0.54 |
3 | 4.77 |
2 | 12.88 |
1 | 75.56 |
A model of ERK activation
The second example employed here is a model of extracellular signal-regulated kinase (ERK) phosphorylation mediated via the epidermal growth factor (EGF) and the nerve growth factor (NGF) receptor pathways that was originally detailed in Sasagawa et al. [42]. This biological system commonly arises in the study of cancer and pain, and remains an area of ongoing clinical significance. This is a relatively large biochemical model describing 150 reactions and 99 species. It is also an interesting model in that it integrates two receptor pathways into one, allowing studies to be undertaken as to how they interact. Due to its size and clinical relevance, the model represents a prime candidate for the application of model reduction techniques. The SBML representation of the Sasagawa et al. model employed in this example is available at www.ebi.ac.uk/biomodels-main/BIOMD0000000049.
Maximal relative error \(\varepsilon\) results for the reduction of the ERK activation model via proper lumping
Dimension | Lumping error (%) |
---|---|
75 | \(\approx 0\) |
50 | 0.01 |
25 | 0.52 |
15 | 1.26 |
14 | 2.21 |
13 | 2.29 |
12 | 1.21 |
11 | 3.07 |
10 | 6.02 |
9 | 10.96 |
8 | 13.12 |
7 | 14.18 |
6 | 29.53 |
5 | 39.03 |
4 | 46.47 |
3 | 54.67 |
2 | 53.52 |
1 | 55.73 |
In the case of the PBPK model, it was assumed that the therapeutic compartment of interest was the brain and that a dose of an antagonist that binds with the EGF receptor was administered orally at \(t=0\). Once again the model parameterisation is given in Tables 1 and 2. We sought to reduce the PBPK model via balanced truncation whilst seeking to preserve accuracy in the intravenous and brain compartments. In order to maintain sufficient accuracy in the brain compartment reduction via balanced truncation required the retention of 4 state-variables in the reduced PBPK model. This yielded a maximal relative error across both the intravenous and brain compartments of 4.9, 3.8, and 9.2% in modelling the pharmacokinetics of pindolol, midazolam, and thiopental respectively.
Conclusions
This article has provided an account of how a model of PBPK can both be reduced and linked to systems biology type models describing target scale responses to drug administration. Doing so yields a model of enhanced pharmacodynamics or QSP that describes drug administration, metabolism, and action across multiple scales.
Crucial to the practical use of such systems is the application of model reduction methods, such as lumping and balanced truncation. Without such methods, models will typically be highly complex and intractable in the context of clinical trial data. However, as has been demonstrated throughout this paper these approaches can enable the construction of significantly simplified systems that still accurately replicate the model’s original behaviour. These models are then sufficiently simplified to be informed by and fitted against clinical trial data whilst maintaining their descriptive power across multiple scales.
This paper has focused specifically on the methods of balanced truncation and lumping for their ability to preserve input–output behaviour in reduced systems across a range of inputs. Balanced truncation was employed for the decomposed linear components of the network due to its superior properties in this regard, whilst lumping is employed for the nonlinear components. Other methods such as time-scale analysis or sensitivity analysis based approaches (outlined in much greater detail in our recent review paper [47]) could also have been considered, but their specific emphases and approaches make them less obvious choices. Throughout the paper we have sought to show how the methods might be best deployed in parallel, by aiming to decompose the overall model based upon the property of linearity and then applying each method due to its suitability based upon this criterion.
We compared the use of balanced truncation in reducing PBPK models to the more commonly applied method of proper lumping. It was demonstrated that balanced truncation can produce a more accurate reduced system than lumping. Additionally, the method is also guaranteed to produce reduced systems that reproduce the input–output behaviour not only locally to the tested inputs, but globally. As a result it represents an excellent choice for reducing the overall ‘gateway’ of the model—the point at which the main input, dosing, interacts with the system. The downside is that this approach somewhat obfuscates the meaning of the compartments in the reduced system. As a result, it is best employed in situations where a ‘black-box’ reduced system is acceptable; more specifically, it is most appropriate in situations where the structure of the reduced model is not of crucial importance, but the accuracy of its predictions as compared with the original model are.
Whilst the linked models created by the approach described in this paper have a wide range of potential benefits, there also exist a number of current limitations to their application. In particular, validation of such models is challenging; whilst clinical trials often collect data on intravenous drug concentration over time and data on the clinical endpoints observed, in vivo data on the dynamics of the subcellular species is typically not available. Additionally, mechanistically modelling how subcellular effects map to the clinical outcomes observed at the whole-body scale may require further modelling efforts. At a simpler level, even questions such as what degree of error should be tolerated in model reduction and how to select the most appropriate reduced model for a specific application remain unanswered.
Finally, the question of how best to link the intracellular and pharmacokinetic scales remains an important one. The method presented here seeks to couple the models in such a way that the outputs of one model can be treated as the inputs of the other, and vice versa. By using automated methods of reduction guaranteed to maintain the input–output behaviour across a reasonable range of inputs, this approach will give accurate reduced linked models. However, the specific form and extent of the inputs and outputs that it is necessary to define to achieve this coupling will end up limiting and defining the reduction it is possible to achieve. In short the overall reduction obtainable is likely to be improved the fewer points of coupling are required. Whilst reduction is likely to perform better the fewer inputs and outputs are defined, and the examples given in this paper possess only a single input and single output, the overall methodology remains valid for the general case of any number of defined inputs and outputs.
Irrespective of these limitations, however, the value of employing model reduction and linking in the construction of QSP models should not be understated. This approach enables us to start with pre-existing physiologically based models at multiple scales of drug activity and construct integrated, reduced models that maintain a mechanistic basis, but that are of a tractable scale. Through the use of model reduction, it is possible to shrink both the parameter space and the number of state-variables modelled. In combination with the often substantial speed-ups in simulation times observed, these approaches can make a range of computational approaches (including parameter fitting) more attainable. By selectively applying model reduction to specific portions of a network it is further possible to produce simplified systems that maintain physiological, molecular-scale detail for specific mechanisms of interest. The influence of the remainder of the system can be accounted for with a lesser degree of specificity. These directly reduced networks enable the study of specific forms of parameter variation including, for example, how patient variability at the level of protein expression might feed through to differences in dose-response. Overall, the approach outlined in this paper can be seen as providing a route to models that contain a medium level of granularity between the fully systemic level of modern approaches and the more empirical classical approaches, whilst still maintaining a physiological basis in model interpretability. By providing the tools to predict differences in patient response and consider optimal dosing strategies in a more mechanistic light, this can be seen as one stepping stone towards the ultimate goal of personalised medicine.
We feel that methods of model reduction have a vital role to play in the continuing development of QSP and that the topics discussed in this paper are fertile ground for future research. Where researchers now seek to quantitatively describe drug action in more complete terms than historical approaches allow, it is necessary that we reflect on the perennial issue of model complexity and the preservation of practical applicability.
Notes
Acknowledgements
Continuous funding was provided by the Engineering and Physical Sciences Research Council (Grant Numbers: EP/P505682/1, EP/J500501/1, and EP/M506606/1) and additional support was provided by Pfizer Global Research and Development in the form of a Ph.D. CASE studentship.
Supplementary material
References
- 1.Anderson J, Chang YC, Papachristodoulou A (2011) Model decomposition and reduction tools for large-scale networks in systems biology. Automatica 47(6):1165–1174CrossRefGoogle Scholar
- 2.Antoulas A (2005) Approximation of large-scale dynamical systems. Advances in design and control. Society for Industrial and Applied Mathematics, PhiladelphiaGoogle Scholar
- 3.Apri M, de Gee M, Molenaar J (2012) Complexity reduction preserving dynamical behavior of biochemical networks. J Theor Biol 304:16–26PubMedCrossRefGoogle Scholar
- 4.Brochot C, Tóth J, Bois FY (2005) Lumping in pharmacokinetics. J Pharmacokinet Pharmacodyn 32(5–6):719–736PubMedCrossRefGoogle Scholar
- 5.Bruggeman FJ, Westerhoff HV, Hoek JB, Kholodenko BN (2002) Modular response analysis of cellular regulatory networks. J Theor Biol 218(4):507–520PubMedCrossRefGoogle Scholar
- 6.Choi J, Yang KW, Lee TY, Lee SY (2008) New time-scale criteria for model simplification of bio-reaction systems. BMC Bioinform 9(1):338CrossRefGoogle Scholar
- 7.Danø S, Madsen MF, Schmidt H, Cedersund G (2006) Reduction of a biochemical model with preservation of its basic dynamic properties. FEBS J 273(21):4862–4877PubMedCrossRefGoogle Scholar
- 8.Degenring D, Froemel C, Dikta G, Takors R (2004) Sensitivity analysis for the reduction of complex metabolism models. J Process Control 14(7):729–745CrossRefGoogle Scholar
- 9.Dokoumetzidis A, Aarons L (2009) Proper lumping in systems biology models. IET Syst Biol 3(1):40–51PubMedCrossRefGoogle Scholar
- 10.Dokoumetzidis A, Aarons L (2009) A method for robust model order reduction in pharmacokinetics. J Pharmacokinet Pharmacodyn 36(6):613–628PubMedCrossRefGoogle Scholar
- 11.Dullerud GE, Paganini F (2000) A course in robust control theory, vol 6. Springer, New YorkCrossRefGoogle Scholar
- 12.Fronton L, Pilari S, Huisinga W (2014) Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn 41(2):87–107PubMedCrossRefGoogle Scholar
- 13.Gerdtzen ZP, Daoutidis P, Hu WS (2004) Non-linear reduction for kinetic models of metabolic reaction networks. Metab Eng 6(2):140–154PubMedCrossRefGoogle Scholar
- 14.Gulati A, Isbister G, Duffull S (2014) Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data. CPT Pharmacomet Syst Pharmacol 3(1):e90CrossRefGoogle Scholar
- 15.Härdin H, van Schuppen J (2006) System reduction of nonlinear positive systems by linearization and truncation. In: C Commault, N Marchand (eds) Positive systems proceedings of the second multidisciplinary international symposium on positive systems: theory and applications. Lecture Notes in Control and Information Sciences. Springer, Berlin, vol 341, pp 431–438Google Scholar
- 16.Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM (2012) Merging systems biology with pharmacodynamics. Sci Transl Med 4(126):1–7CrossRefGoogle Scholar
- 17.Jones H, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol 2(8):e63CrossRefGoogle Scholar
- 18.Jones HM, Gardner IB, Watson KJ (2009) Modelling and PBPK simulation in drug discovery. AAPS J 11(1):155–166PubMedPubMedCentralCrossRefGoogle Scholar
- 19.Klipp E, Liebermeister W, Wierling C, Kowald A, Lehrach H, Herwig R (2013) Systems biology. Wiley, BerlinGoogle Scholar
- 20.Konopka AK (2006) Systems biology: principles, methods, and concepts. CRC Press, Boca RatonCrossRefGoogle Scholar
- 21.Koschorreck M, Conzelmann H, Ebert S, Ederer M, Gilles ED (2007) Reduced modeling of signal transduction-a modular approach. BMC Bioinform 8(1):336CrossRefGoogle Scholar
- 22.Kourdis PD, Steuer R, Goussis DA (2010) Physical understanding of complex multiscale biochemical models via algorithmic simplification: glycolysis in Saccharomyces cerevisiae. Physica D 239(18):1798–1817CrossRefGoogle Scholar
- 23.Kourdis PD, Palasantza AG, Goussis DA (2013) Algorithmic asymptotic analysis of the NF-\(\kappa\)B signaling system. Comput Math Appl 65(10):1516–1534CrossRefGoogle Scholar
- 24.Krippendorff BF, Oyarzun DA, Huisinga W (2012) Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 39(2):125–139PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Kuo JC, Wei J (1969) Lumping analysis in monomolecular reaction systems. analysis of approximately lumpable system. Ind Eng Chem Fundam 8(1):124–133CrossRefGoogle Scholar
- 26.Lawless A, Nichols N, Boess C, Bunse-Gerstner A (2008) Using model reduction methods within incremental four-dimensional variational data assimilation. Mon Weather Rev 136(4):1511–1522CrossRefGoogle Scholar
- 27.Liebermeister W, Baur U, Klipp E (2005) Biochemical network models simplified by balanced truncation. FEBS J 272(16):4034–4043PubMedCrossRefGoogle Scholar
- 28.Liu G, Swihart MT, Neelamegham S (2005) Sensitivity, principal component and flux analysis applied to signal transduction: the case of epidermal growth factor mediated signaling. Bioinformatics 21(7):1194–1202PubMedCrossRefGoogle Scholar
- 29.Maurya M, Bornheimer S, Venkatasubramanian V, Subramaniam S (2005) Reduced-order modelling of biochemical networks: application to the GTPase-cycle signalling module. IEE Proc Syst Biol 152(4):229–242CrossRefGoogle Scholar
- 30.Maurya M, Bornheimer S, Venkatasubramanian V, Subramaniam S (2009) Mixed-integer nonlinear optimisation approach to coarse-graining biochemical networks. IET Syst Biol 3(1):24–39PubMedPubMedCentralCrossRefGoogle Scholar
- 31.Moore B (1981) Principal component analysis in linear systems: controllability, observability, and model reduction. IEEE Trans Autom Control 26(1):17–32CrossRefGoogle Scholar
- 32.Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42(10):883–908PubMedCrossRefGoogle Scholar
- 33.Nestorov IA, Aarons LJ, Arundel PA, Rowland M (1998) Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 26(1):21–46PubMedCrossRefGoogle Scholar
- 34.Okino MS, Mavrovouniotis ML (1998) Simplification of mathematical models of chemical reaction systems. Chem Rev 98(2):391–408PubMedCrossRefGoogle Scholar
- 35.Pernebo L, Silverman L (1982) Model reduction via balanced state space representations. IEEE Trans Autom Control 27(2):382–387CrossRefGoogle Scholar
- 36.Petrov V, Nikolova E, Wolkenhauer O (2007) Reduction of nonlinear dynamic systems with an application to signal transduction pathways. Syst Biol IET 1(1):2–9CrossRefGoogle Scholar
- 37.Pilari S, Huisinga W (2010) Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 37(4):365–405PubMedCrossRefGoogle Scholar
- 38.Prescott TP, Papachristodoulou A (2012) Guaranteed error bounds for structured complexity reduction of biochemical networks. J Theor Biol 304:172–182PubMedCrossRefGoogle Scholar
- 39.Prescott TP, Papachristodoulou A (2014) Layered decomposition for the model order reduction of timescale separated biochemical reaction networks. J Theor Biol 356:113–122PubMedCrossRefGoogle Scholar
- 40.Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238–1257PubMedCrossRefGoogle Scholar
- 41.Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94(6):1259–1276PubMedCrossRefGoogle Scholar
- 42.Sasagawa S, Ozaki YI, Fujita K, Kuroda S (2005) Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 7(4):365–373PubMedCrossRefGoogle Scholar
- 43.Schneider KR, Wilhelm T (2000) Model reduction by extended quasi-steady-state approximation. J Math Biol 40(5):443–450PubMedCrossRefGoogle Scholar
- 44.Skogestad S, Postlethwaite I (2005) Multivariable feedback control: analysis and design. Wiley, New YorkGoogle Scholar
- 45.Smets I, Bernaerts K, Sun J, Marchal K, Vanderleyden J, Van Impe J (2002) Sensitivity function-based model reduction: a bacterial gene expression case study. Biotechnol Bioeng 80(2):195–200PubMedCrossRefGoogle Scholar
- 46.Snowden TJ, van der Graaf PH, Tindall MJ (2017) A combined model reduction algorithm for controlled biochemical systems. BMC Syst Biol 11(1):17. https://doi.org/10.1186/s12918-017-0397-1
- 47.Snowden TJ, van der Graaf PH, Tindall MJ (2017) Methods of model reduction for large-scale biological systems: a survey of current methods and trends. Bull Math Biol 79(7):1449–1486. https://doi.org/10.1007/s11538-017-0277-2
- 48.Sootla A, Anderson J (2014) On projection-based model reduction of biochemical networks—Part I: the deterministic case. arXiv preprint arXiv:1403.3579
- 49.Sorger PK, Allerheiligen SR, Abernethy DR, Altman RB, Brouwer KL, Califano A, D’Argenio DZ, Iyengar R, Jusko WJ, Lalonde, R, et al (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. In: An NIH white paper by the QSP workshop group-October, vol 2011Google Scholar
- 50.Sunnåker M, Schmidt H, Jirstrand M, Cedersund G (2010) Zooming of states and parameters using a lumping approach including back-translation. BMC Syst Biol 4(1):28PubMedPubMedCentralCrossRefGoogle Scholar
- 51.Sunnåker M, Cedersund G, Jirstrand M (2011) A method for zooming of nonlinear models of biochemical systems. BMC Syst Biol 5(1):140PubMedPubMedCentralCrossRefGoogle Scholar
- 52.Surovtsova I, Zobeleya J (2006) Focusing on dynamic dimension reduction for biochemical reaction systems. In: Cánovas M, Iborra J, Manjón A (eds) Understanding and exploiting systems biology in biomedicine and bioprocesses. Lecture Notes in Control and Information Sciences. Fundación CajaMurcia, Murcia, pp 31–45Google Scholar
- 53.Surovtsova I, Simus N, Lorenz T, König A, Sahle S, Kummer U (2009) Accessible methods for the dynamic time-scale decomposition of biochemical systems. Bioinformatics 25(21):2816–2823PubMedCrossRefGoogle Scholar
- 54.Surovtsova I, Simus N, Hübner K, Sahle S, Kummer U (2012) Simplification of biochemical models: a general approach based on the analysis of the impact of individual species and reactions on the systems dynamics. BMC Syst Biol 6(1):14PubMedPubMedCentralCrossRefGoogle Scholar
- 55.Taylor SR, Petzold LR et al (2008) Oscillator model reduction preserving the phase response: application to the circadian clock. Biophys J 95(4):1658–1673PubMedPubMedCentralCrossRefGoogle Scholar
- 56.Tindall M, Porter S, Wadhams G, Maini P, Armitage J (2009) Spatiotemporal modelling of CheY complexes in Escherichia coli chemotaxis. Prog Biophys Mol Biol 100(1):40–46PubMedCrossRefGoogle Scholar
- 57.Tsamandouras N, Rostami-Hodjegan A, Aarons L (2015) Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting pbpk models to observed clinical data. Br J Clin Pharmacol 79(1):48–55PubMedCrossRefGoogle Scholar
- 58.Vallabhajosyula RR, Chickarmane V, Sauro HM (2006) Conservation analysis of large biochemical networks. Bioinformatics 22(3):346–353PubMedCrossRefGoogle Scholar
- 59.van der Graaf PH, Benson N (2011) Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 28(7):1460–1464PubMedCrossRefGoogle Scholar
- 60.van der Greef J, McBurney RN (2005) Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 4(12):961–967PubMedCrossRefGoogle Scholar
- 61.van Hasselt JC, van der Graaf PH (2015) Towards integrative systems pharmacology models in oncology drug development. Drug Discov Today Technol 15:1–8PubMedCrossRefGoogle Scholar
- 62.Wei J, Kuo JC (1969) Lumping analysis in monomolecular reaction systems. analysis of the exactly lumpable system. Ind Eng Chem Fundam 8(1):114–123CrossRefGoogle Scholar
- 63.Workgroup EM, Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O, Frey N, Hamrn B, Harnisch L, Ivanow F, Kerbusch T, Lippert J, Milligan P, Rohou S, Staab A, Steimer J, Torne C, Visser S (2016) Good practices in model-informed drug discovery and development: Practice, application, and documentation. CPT Pharmacomet Syst Pharmacol 5(3):93–122. https://doi.org/10.1002/psp4.12049 CrossRefGoogle Scholar
- 64.Yates JWT (2006) Structural identifiability of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 33(4):421–439. https://doi.org/10.1007/s10928-006-9011-7
- 65.Zhao S, Iyengar R (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52:505PubMedPubMedCentralCrossRefGoogle Scholar
Copyright information
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.